Etiology, 3-Month Functional Outcome and Recurrent Events in Non-Traumatic Intracerebral Hemorrhage
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Knowledge about different etiologies of non-traumatic intracerebral hemorrhage (ICH) and their outcomes is scarce. Methods We assessed prevalence of pre-specified ICH etiologies and their association with outcomes in consecutive ICH patients enrolled in the prospective Swiss Stroke Registry (2014 to 2019). Results We included 2,650 patients (mean±standard deviation age 72±14 years, 46.5% female, median National Institutes of Health Stroke Scale 8 [interquartile range, 3 to 15]). Etiology was as follows: hypertension, 1,238 (46.7%); unknown, 566 (21.4%); antithrombotic therapy, 227 (8.6%); cerebral amyloid angiopathy (CAA), 217 (8.2%); macrovascular cause, 128 (4.8%); other determined etiology, 274 patients (10.3%). At 3 months, 880 patients (33.2%) were functionally independent and 664 had died (25.1%). ICH due to hypertension had a higher odds of functional independence (adjusted odds ratio [aOR], 1.33; 95% confidence interval [CI], 1.00 to 1.77; P=0.05) and lower mortality (aOR, 0.64; 95% CI, 0.47 to 0.86; P=0.003). ICH due to antithrombotic therapy had higher mortality (aOR, 1.62; 95% CI, 1.01 to 2.61; P=0.045). Within 3 months, 4.2% of patients had cerebrovascular events. The rate of ischemic stroke was higher than that of recurrent ICH in all etiologies but CAA and unknown etiology. CAA had high odds of recurrent ICH (aOR, 3.38; 95% CI, 1.48 to 7.69; P=0.004) while the odds was lower in ICH due to hypertension (aOR, 0.42; 95% CI, 0.19 to 0.93; P=0.031). Conclusions Although hypertension is the leading etiology of ICH, other etiologies are frequent. One-third of ICH patients are functionally independent at 3 months. Except for patients with presumed CAA, the risk of ischemic stroke within 3 months of ICH was higher than the risk of recurrent hemorrhage.
Abstract
Background and Purpose Knowledge about different etiologies of non-traumatic intracerebral hemorrhage (ICH) and their outcomes is scarce. Methods We assessed prevalence of pre-specified ICH etiologies and their association with outcomes in consecutive ICH patients enrolled in the prospective Swiss Stroke Registry (2014 to 2019). Results We included 2,650 patients (mean±standard deviation age 72±14 years, 46.5% female, median National Institutes of Health Stroke Scale 8 [interquartile range, 3 to 15]). Etiology was as follows: hypertension, 1,238 (46.7%); unknown, 566 (21.4%); antithrombotic therapy, 227 (8.6%); cerebral amyloid angiopathy (CAA), 217 (8.2%); macrovascular cause, 128 (4.8%); other determined etiology, 274 patients (10.3%). At 3 months, 880 patients (33.2%) were functionally independent and 664 had died (25.1%). ICH due to hypertension had a higher odds of functional independence (adjusted odds ratio [aOR], 1.33; 95% confidence interval [CI], 1.00 to 1.77; P=0.05) and lower mortality (aOR, 0.64; 95% CI, 0.47 to 0.86; P=0.003). ICH due to antithrombotic therapy had higher mortality (aOR, 1.62; 95% CI, 1.01 to 2.61; P=0.045). Within 3 months, 4.2% of patients had cerebrovascular events. The rate of ischemic stroke was higher than that of recurrent ICH in all etiologies but CAA and unknown etiology. CAA had high odds of recurrent ICH (aOR, 3.38; 95% CI, 1.48 to 7.69; P=0.004) while the odds was lower in ICH due to hypertension (aOR, 0.42; 95% CI, 0.19 to 0.93; P=0.031). Conclusions Although hypertension is the leading etiology of ICH, other etiologies are frequent. One-third of ICH patients are functionally independent at 3 months. Except for patients with presumed CAA, the risk of ischemic stroke within 3 months of ICH was higher than the risk of recurrent hemorrhage.
참고문헌 (31)
- Cordonnier C, "Intracerebral haemorrhage : current approaches to acute management", Lancet, 392, pp.1257~1268 (2018)
- Hostettler IC, "Intracerebral hemorrhage : an update on diagnosis and treatment", Expert Rev Neurother, 19, pp.679~694 (2019)
- Shoamanesh A, "Canadian stroke best practice recommendations: management of spontaneous intracerebral hemorrhage, 7th edition update 2020", Int J Stroke, 16, pp.321~341 (2021)
- Steiner T, "European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage", Int J Stroke, 9, pp.840~855 (2014)
- Adams HP Jr, "Classification of subtype of acute ischemic stroke:definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment", Stroke, 24, pp.35~41 (1993)
- Amarenco P, "Classification of stroke subtypes", Cerebrovasc Dis, 27, pp.493~501 (2009)
- Ay H, "A computerized algorithm for etiologic classification of ischemic stroke : the Causative Classification of Stroke System", Stroke, 38, pp.2979~2984 (2007)
- Rannikmäe K, "Reliability of intracerebral hemorrhage classification systems : a systematic review", Int J Stroke, 11, pp.626~636 (2016)
- Banerjee G, "Longer term stroke risk in intracerebral haemorrhage survivors", J Neurol Neurosurg Psychiatry, 91, pp.840~845 (2020)
- Casolla B, "Five-year risk of major ischemic and hemorrhagic events after intracerebral hemorrhage", Stroke, 50, pp.1100~1107 (2019)
- Charidimou A, "Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: a meta-analysis", Neurology, 89, pp.820~829 (2017)
- Poon MT, "Long-term prognosis after intracerebral haemorrhage : systematic review and meta-analysis", J Neurol Neurosurg Psychiatry, 85, pp.660~667 (2014)
- Meretoja A, "SMASH-U : a proposal for etiologic classification of intracerebral hemorrhage", Stroke, 43, pp.2592~2597 (2012)
- Martí-Fàbregas J, "SMASH-U versus H-ATOMIC : a head-to-head comparison for the etiologic classification of intracerebral hemorrhage", J Stroke Cerebrovasc Dis, 27, pp.2375~2380 (2018)
- Martí-Fàbregas J, "The H-ATOMIC criteria for the etiologic classification of patients with intracerebral hemorrhage", PLoS One, 11, pp.e0156992~ (2016)
- Ringelstein EB, "European Stroke Organisation recommendations to establish a stroke unit and stroke center", Stroke, 44, pp.828~840 (2013)
- Manno C, "Outcome of endovascular therapy in stroke with large vessel occlusion and mild symptoms", Neurology, 93, pp.e1618~e1626 (2019)
- Meinel TR, "Prior anticoagulation in patients with ischemic stroke and atrial fibrillation", Ann Neurol, 89, pp.42~53 (2021)
- Rodrigues MA, "The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy : model development and diagnostic test accuracy study", Lancet Neurol, 17, pp.232~240 (2018)
- Varmdal T, "Inter-rater reliability of a national acute stroke register", BMC Res Notes, 8, pp.584~ (2015)
- Meretoja A, "Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial", Lancet Neurol, 19, pp.980~987 (2020)
- Béjot Y, "Intracerebral haemorrhage profiles are changing:results from the Dijon population-based study", Brain, 136(Pt 2), pp.658~664 (2013)
- Seiffge DJ, "Hematoma location and morphology of anticoagulation-associated intracerebral hemorrhage", Neurology, 92, pp.e782~e791 (2019)
- Seiffge DJ, "Small vessel disease burden and intracerebral haemorrhage in patients taking oral anticoagulants", J Neurol Neurosurg Psychiatry, 92, pp.805~814 (2021)
- Palm F, "Intracerebral haemorrhage in a population-based stroke registry (LuSSt): incidence, aetiology, functional outcome and mortality", J Neurol, 260, pp.2541~2550 (2013)
- Lioutas VA, "Cerebral small vessel disease burden and functional and radiographic outcomes in intracerebral hemorrhage", J Neurol, 265, pp.2803~2814 (2018)
- Sprigg N, "Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial", Lancet, 391, pp.2107~2115 (2018)
- Hanley DF, "Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial", Lancet, 393, pp.1021~1032 (2019)
- Sembill JA, "Severity assessment in maximally treated ICH patients : the max-ICH score", Neurology, 89, pp.423~431 (2017)
- Tilling EJ, "Do clinicians overestimate the severity of intracerebral hemorrhage", Stroke, 50, pp.344~348 (2019)
- Kuramatsu JB, "Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage", JAMA, 313, pp.824~836 (2015)